Treatment options for the fetus with alloimmune hemolytic disease.
Bowman
J M
JM
Department of Pediatrics and Child Health, Faculty of Medicine, University of Manitoba, Winnipeg, Canada.
D001805:Blood Transfusion, Intrauterine / Q000009:adverse effects / Q000379:methods; D002170:Canada / Q000453:epidemiology; D004899:Erythroblastosis, Fetal / Q000175:diagnosis / Q000453:epidemiology / Q000276:immunology / Q000628:therapy*; D005078:Exchange Transfusion, Whole Blood; D005260:Female; D005312:Fetal Blood / Q000276:immunology; D005313:Fetal Death / Q000209:etiology; D006801:Humans; D015160:Hydrops Fetalis / Q000209:etiology / Q000401:mortality / Q000517:prevention & control; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D007165:Immunosuppression Therapy; D007231:Infant, Newborn; D007647:Kernicterus / Q000209:etiology / Q000401:mortality / Q000517:prevention & control; D007751:Labor, Induced; D008297:Male; D010951:Plasma Exchange; D011237:Predictive Value of Tests; D011247:Pregnancy / Q000276:immunology; D011296:Prenatal Diagnosis; D015995:Prevalence; D012203:Rh Isoimmunization / Q000150:complications / Q000453:epidemiology / Q000628:therapy; D012204:Rh-Hr Blood-Group System / Q000276:immunology
D016756:Immunoglobulins, Intravenous; D012204:Rh-Hr Blood-Group System